Zynex, Inc. (ZYXI) Stock Analysis

Zynex, Inc. (ZYXI) Healthcare & Pipeline Overview

Zynex, Inc. focuses on developing and distributing medical devices for pain management, rehabilitation, and fluid monitoring. Its key products include electrical stimulation devices like NexWave and fluid monitoring systems, targeting the chronic and acute pain markets through a direct sales force in the United States.

What Is the Investment Thesis for ZYXI?

Zynex operates in the growing medical device market, specifically targeting pain management and rehabilitation. The company's direct sales model allows for focused market penetration within the United States. The gross margin of 71.6% indicates strong pricing power and efficient manufacturing. Upcoming catalysts include potential expansion of the fluid monitoring product line and increased adoption of the NexWave device. However, the negative profit margin of -68.4% raises concerns about profitability and cost management. Investors should monitor the company's ability to achieve sustainable profitability and manage operating expenses effectively.

Based on FMP financials and quantitative analysis

ZYXI Key Highlights

Gross margin of 71.6% demonstrates strong pricing power in the medical device market.

• Direct sales force enables targeted market penetration within the United States.
• Offers a diverse product line including electrical stimulation devices and fluid monitoring systems.
• Beta of 1.00 indicates market correlation.
• Headquartered in Englewood, Colorado, with approximately 1,000 employees.

Who Are ZYXI's Competitors?

ZYXI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ZYXI's Key Strengths?

Direct sales force in the United States.

• Proprietary technology in electrical stimulation.
• Diverse product portfolio.
• High gross margin.

What Are ZYXI's Weaknesses?

Negative profit margin.

• Limited geographic presence (primarily US).
• Reliance on direct sales model.
• Small market capitalization.

What Could Drive ZYXI Stock Higher?

ZYXI catalyst: Potential expansion of the fluid monitoring product line (CM-1500 and CM-1600) into more hospitals and surgical centers.

• Increased adoption of the NexWave device as a non-opioid pain management solution.
• Continued efforts to expand the direct sales force and reach more physicians and therapists in the United States.

What Are the Key Risks for ZYXI?

Financial-distress signal — its Altman Z-Score of -4.98 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Negative profit margin raises concerns about the company's financial sustainability.
• Competition from larger, more established medical device manufacturers.
• Regulatory changes impacting the approval and marketing of medical devices.
• Economic downturn affecting healthcare spending and demand for Zynex's products.

What Are the Growth Opportunities for ZYXI?

• Expansion of Fluid Monitoring Systems: Zynex's CM-1500 and CM-1600 fluid monitoring systems offer a growth avenue in operating and recovery rooms. The market for non-invasive fluid monitoring is expanding due to the need for accurate and real-time fluid management during surgical procedures. Increased adoption of these systems could significantly contribute to revenue growth. The timeline for market penetration depends on regulatory approvals and hospital adoption rates.
• Increased Adoption of NexWave: The NexWave device, a multi-modal electrical stimulation device, presents a growth opportunity in pain management. As an alternative to opioid-based pain relief, NexWave can capitalize on the growing demand for non-pharmacological pain management solutions. The company's direct sales force can drive adoption among physicians and therapists.
• Geographic Expansion: While currently focused on the United States, Zynex could explore international markets for its products. Expanding into Europe or Asia could unlock new revenue streams and diversify the company's geographic risk. The timeline for international expansion would depend on regulatory approvals and market entry strategies. The global market for medical devices is significantly larger than the US market alone.
• New Product Development: Investing in research and development to create new medical devices and improve existing products can drive long-term growth. Developing innovative solutions for pain management, rehabilitation, or fluid monitoring can attract new customers and differentiate Zynex from competitors. The timeline for new product development depends on the complexity of the device and regulatory approval processes.
• Strategic Partnerships and Acquisitions: Zynex could pursue strategic partnerships or acquisitions to expand its product portfolio or market reach. Partnering with other medical device companies or acquiring complementary businesses can accelerate growth and create synergies. The timeline for partnerships and acquisitions depends on identifying suitable targets and negotiating favorable terms.

What Are ZYXI's Competitive Advantages?

• Direct sales force provides a competitive advantage in reaching physicians and therapists.
• Proprietary technology in electrical stimulation devices.
• Established brand reputation in the pain management market.
• Diverse product portfolio catering to various medical needs.

What Does ZYXI Do?

Zynex, Inc., founded in 1996 and headquartered in Englewood, Colorado, operates as a medical device company specializing in the design, manufacture, and marketing of products aimed at pain management, rehabilitation, and fluid monitoring. The company's core business revolves around electrical stimulation devices, including the NexWave, a multi-modal device utilizing interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES). These devices are marketed directly to physicians and therapists through a dedicated field sales team. Zynex also offers NeuroMove, an electromyography-triggered electrical stimulation device, InWave for female urinary incontinence, and E-Wave, an NMES device. In addition to its proprietary devices, Zynex supplies private-labeled products such as electrodes and batteries used in electrotherapy. The company also distributes complementary products, including Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces, and knee braces. Expanding its product line, Zynex offers the Zynex Fluid Monitoring System (CM-1500) and Zynex Wireless Fluid Monitoring System (CM-1600), non-invasive devices used to monitor fluid volume changes during surgery and recovery. The company also provides the NiCO CO-Oximeter and HemeOx tHb Oximeter for hemodynamic and pulse oximetry monitoring. Zynex's products cater to various applications, including pain management, stroke and spinal cord injury rehabilitation, hemodynamic monitoring, and pulse oximetry monitoring, primarily within the United States.

What Products and Services Does ZYXI Offer?

• Designs and manufactures medical devices for pain management.
• Offers electrical stimulation devices like NexWave for chronic and acute pain.
• Provides devices for muscle activation and rehabilitation.
• Markets fluid monitoring systems for use in operating and recovery rooms.
• Sells private-labeled products, including electrodes and batteries.
• Distributes complementary products like cervical traction devices and back braces.

How Does ZYXI Make Money?

• Designs, manufactures, and markets medical devices.
• Sells products through a direct sales force in the United States.
• Generates revenue from device sales and related accessories.
• Offers private-labeled products and distributes complementary devices.

What Industry Does ZYXI Operate In?

Zynex operates within the medical device industry, which is characterized by technological advancements, stringent regulatory requirements, and evolving patient needs. The pain management and rehabilitation segments are driven by an aging population and increasing prevalence of chronic conditions. Competition includes established medical device manufacturers and specialized pain management companies. Zynex's direct sales model and focus on non-invasive solutions position it to capture a share of this expanding market.

Who Are ZYXI's Key Customers?

• Physicians specializing in pain management.
• Therapists focused on rehabilitation.
• Hospitals and surgical centers using fluid monitoring systems.
• Patients seeking non-pharmacological pain relief solutions.

Company Profile

Zynex, Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Englewood, US. The company is led by CEO Steven Lewis Dyson. ZYXI has traded publicly since 2004.

Zynex, Inc. (ZYXI) Valuation Context

Valued at $3.80M, ZYXI is classified as a micro-cap stock.

Zynex, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.98 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Zynex, Inc. revenue of about $101.2M for fiscal 2026, with EPS near $-0.48.

ZYXI Financials

ZYXI Latest News

No recent news available for ZYXI.

Common Questions About ZYXI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources